Deciphera Pharmaceuticals (DCPH) Tops Q2 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results
August 4, 2020 4:05 PM EDT- QINLOCKTM Approved for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor and U.S. Commercial Launch Underway -
- Reported QINLOCK Net Revenue of $4.8 Million in the First Partial Quarter of Launch -
- Company Expects to Complete Enrollment in Phase 3 INTRIGUE Study in Fourth Quarter 2020 -
- Second Quarter 2020 Ended with Cash, Cash Equivalents and Marketable Securities of $632 Million; Cash Runway Expected into the Second Half of 2022 -
- Company to Host Conference Call Today at 4:30 PM ET... More
